NCT02978495View on ClinicalTrials.gov

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

December 2, 2019

Study Completion Date

October 22, 2021

Conditions
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Interventions
DRUG

Doxorubicin

Doxorrubicin 60 mg/m2 4 cycles each 21 days

DRUG

Carboplatin

Carboplatin AUC 1,5 once a week, for 12 weeks

DRUG

Paclitaxel

80mg/m2 weekly for 12 weeks

DRUG

Cyclophosphamide

600mg/m2 4 cycles each 21 days

Trial Locations (1)

14784-400

Barretos Cancer Hospital, Barretos

All Listed Sponsors
lead

Barretos Cancer Hospital

OTHER

NCT02978495 - Neoadjuvant Carboplatin in Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter